ClinicalTrials.gg
CompletedNCT05642546Updated Dec 8, 2022

First-in-Human (FIH) Clinical Study of NM8074 in Healthy Adult Volunteers

A Phase 1 interventional study of NM8074 and Placebo in Healthy, sponsored by NovelMed Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-08.

Sponsored by NovelMed Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2022, 4 years 5 months ago, and no results have been posted to the registry.
  • Registered 2 years 3 months after the study started (first participant enrolled Aug 2020, registered Nov 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a Phase 1 randomized, double-blind, placebo-controlled, single administration, sequential cohort with sentinel dosing, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of NM8074 in healthy subjects. This study will include 5 cohorts, with each cohort consisting of a total of 8 healthy subjects, including both males and females, randomized in a 3:1 ratio of NM8074 to placebo (6 subjects assigned to NM8074 and 2 subjects assigned to placebo).

Read the detailed description

NM8074 is a novel, recombinant, humanized monoclonal antibody. NM8074 selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases. Both C3 and C5 convertases are critical for exacerbation and amplification of the AP in complement-mediated disorders. 06-101-FIH-NM8074 is the first-in-human clinical trial for NM8074 which is intended to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of NM8074 when delivered as a single intravenous infusion to healthy volunteers. Doses will be escalated in each of the 5 sequential cohorts using sentinel dosing.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

NovelMed Therapeutics is the lead sponsor of 9 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female subjects ≥18 years to ≤60 years of age, inclusive
  • (BMI) between 18 kg/m2 and 32 kg/m2, inclusive and weigh at least 50 kg
  • (Fridericia's correction [QTcF]); QTcF ≤ 450 msec for males and ≤ 470 msec for females at Screening and prior to dosing on Admittance Day -1
  • Willing and able to give signed and comply with the study visit schedule
  • In good general health as determined by the Investigator's review of medical history, concomitant medications, physical examination, clinical laboratory tests, and evaluations
  • Male subjects must agree to use barrier (male condom) and not donate sperm during the treatment period and for at least 3 months after the last dose of NM8074. Barrier contraception is required even with documented medical assessment of the surgical success of a vasectomy
  • Female subjects who are of must use highly effective contraception1 or acceptable contraception as defined below, starting at screening and continuing until at least 3 months after the last dose of NM8074. Female subjects must not donate ova during the screening and treatment periods and for at least 3 months after the last dose of NM8074

Highly effective contraceptive methods for female subjects are as follows:

a. Combined (estrogen and progesterone containing) hormonal contraception associated with inhibition of ovulation: i. Oral contraceptives (e.g., oral, injected, implanted) or intrauterine ii. Intravaginal iii. Transdermal b. Progesterone-only hormonal contraception associated with inhibition of ovulation: i. Oral ii. Injectable iii. Implantable c. Intrauterine Device d. Intrauterine hormone-releasing system e. Bilateral tubal occlusion/tubal ligation (or comparable procedure)

  • Women of Non-childbearing Potential

    a. : i. 12 continuous months of natural (spontaneous) amenorrhea without an alternative medical cause and a serum follicle-stimulating hormone (FSH) level

    • 40 mIU/mL ii. 6 weeks after surgical bilateral oophorectomy with or without hysterectomy b. Post-hysterectomy
  • Sexual Abstinence Subjects who practice true abstinence, because of the subject's lifestyle choice (i.e., the subject should not become abstinent just for the purpose of study participation), are exempt from contraceptive requirements. Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception. For subjects who practice true abstinence, subjects must be abstinent for at least 6 months prior to screening and must agree to remain abstinent from the time of signing the Informed Consent Form until the end of study.
  • Same-sex Relationships For subjects who are exclusively in same-sex relationships, contraceptive requirements do not apply. A subject in a same-sex relationship at the time of signing the Informed Consent Form (ICF) must agree to refrain from engaging in a heterosexual relationship from the time of signing the ICF until the end of study
  • Has received the MenB Bexsero® vaccination against Neisseria meningitidis serogroup B (consisting of 2 intramuscular injections, 30 days apart) with the first injection at least 45 days prior to study drug initiation, and the second injection no later than 15 days prior to study drug initiation, and/or provides documentation of positive titer response precluding revaccination
  • Has received the MenACWY Menactra® polysaccharide diphtheria toxoid conjugate vaccine solution against Neisseria meningitidis serogroups A, C, Y, and W-135 (consisting of 1 intramuscular injection) at least 45 days prior to study drug initiation with confirmation of response acceptable by PI, and/or provides documentation of positive titer response precluding re-vaccination
  • Negative serum pregnancy test at Screening and Check-In for all female subjects
  • Only non-smokers will take priority in enrollment for the study. Should there be a shortage of available healthy volunteers, light smokers (\~10 cigarettes/day) will be accepted

Exclusion criteria

Exclusion Criteria:

  • Subjects who plan to travel during the course of the study to endemic areas as per the Centers for Disease Control and Prevention (CDC) definition for meningococcal meningitis
  • Has a currently active systemic infection that requires antibiotic, antifungal, antiparasitic, or antiviral medications. Any infection prior to entry into the study must have been cured for 1 month prior to the Screening Visit
  • Positive QuantiFERON®-TB test indicating possible tuberculosis (TB) infection, active systemic bacterial, viral, or fungal infection within 14 days prior to dosing
  • Has a known history of meningococcal/pneumococcal/gonococcal disease
  • to receiving meningococcal vaccine, including severe (life-threatening) allergic reaction to a previous dose of meningococcal serogroup B vaccine; severe (life-threatening) allergy to any vaccine component; previous diagnosis of Guillain-Barré Syndrome
  • History of unexplained, recurrent infection; or infection requiring treatment with systemic antibiotics within the last 90 days prior to dosing
  • History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to the tuberculosis test performed at screening
  • abnormalities in urine upon urinalysis to allow investigator discretion and to prevent disqualifications for minor findings of no significance such as mucus in the urine
  • Any of the following hematology tests: ; total white blood cells (total WBC); absolute neutrophils; and outside the laboratory reference range at Screening and Day -1
  • Abnormal urine tests: Clinically significant abnormalities in urine upon urinalysis" to allow investigator discretion and to prevent disqualifications for minor findings of no significance such as mucus in the urine
  • History of continuous topical/inhaled or systemic use > 1 month or history of any inhaled or topical therapy within 90 days prior to study drug administration
  • Has any history of or active cardiac disease, including congestive heart failure, angina, any arrhythmia, or clinically significant findings on ECGs
  • Has asthma or other severe respiratory disease (e.g., ) requiring daily prescription medication or prior emergency room visits or hospitalization
  • Has a history of solid organ transplantation; or has kidney, neurologic, metabolic, or other organ system disease that, in the Investigator's opinion, precludes participation in this study
  • Has clinically significant liver disease or transaminase ( [ALT] and aspartate aminotransferase [AST] levels > 1.5x the (ULN) measured at Screening and Day-1
  • Has total levels > 1.5x ULN measured at Screening
  • Has an estimated \<70 mL/minute/1.73m2 measured at Screening (measured with or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI))
  • Has an abnormal laboratory finding or vital signs outside the specified normal parameters at the Screening Visit which is judged by the PI as clinically significant
  • Has any clinically significant abnormality at Screening or Check-In
  • History of allergy to of NM8074
  • Use of prescription medications within 28 days prior to study drug administration
  • Has a body temperature >99.5 °F (37.5 °C) a fever associated with a symptomatic viral or bacterial infection) within 2 weeks prior to the first dosing
  • Has an immunological disorder such as, but not limited to, (HIV); acquired or congenital immune deficiency syndrome; diseases, such as, but not limited to, rheumatoid arthritis, systemic lupus erythematosus, vasculitis, or seronegative spondyloarthropathies; or any acute or chronic infection, including, but not limited to, virus (HBV) or virus (HCV)
  • Is pregnant, lactating, or planning a pregnancy
  • Has used any prescribed medication within 14 days prior to the first admission or has plans to use any prescribed medication during the study (with the exception of hormonal )
  • Participation in any experimental small molecule or non-antibody molecule therapy within 60 days prior to dosing on Day 1
  • Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at Screening) of more than 50 mL of blood within 30 days of dosing, or more than 499 mL of blood within 56 days of dosing
  • Immunization with a 1 month prior to dosing or planned vaccination during the course of the study (except for the vaccination planned by the study protocol)
  • History of use of illegal recreational drugs within 1 year prior to Screening
  • Has used any over-the-counter medicinal products, including herbal and dietary supplements, within 7 days prior to the first admission or has plans to use during the study (with the exception of approved daily doses of acetaminophen, ibuprofen, or aspirin for the treatment of minor discomfort)
  • Is currently participating in any other type of clinical trial
  • Has previously been randomized and withdrawn from this study
  • Has active alcohol or substance abuse or history of alcohol or substance abuse within the 6 months prior to randomization or has a positive result on urine drug or breath alcohol screen during the Screening Visit. The use of alcohol is prohibited for 48 hours prior to Check-In and during confinement.
  • Subjects with any medical history, conditions, or risks, which, in the opinion of the Investigator, may interfere with the subject's full participation in the study, or compliance with the protocol, poses any additional risk for the subject, or confounds the assessment of the subject or outcome of the study
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    NM8074

    6 subjects per each of the 5 cohorts will receive a single dose of NM8074 administered via IV (intravenous) infusion at 0.3, 1.0, 3.0, 10, or 20 mg/kg

    Drug: NM8074

  • Placebo comparator
    Placebo

    2 subjects per each of the 5 cohorts will receive saline placebo administered via IV infusion.

    Drug: Placebo

Interventions

  • DrugNM8074

    Novel, recombinant, humanized monoclonal antibody that selectively binds to human Factor Bb with high affinity and blocks the formation of Alternative Pathway (AP) driven C3 and C5 convertases

  • DrugPlacebo

    Saline Placebo

06

What researchers measure

Primary outcomes

  1. Monitoring of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Adverse events will be graded according to the CTCAE v4.03. If the AE term is not described in the grading scales, the AE severity shall be reported according to the following: * Grade I: Mild (awareness of sign or symptom, but easily tolerated) * Grade II: Moderate (discomfort sufficient to cause interference with normal activities) * Grade III: Severe (incapacitating, with inability to perform normal activities) * Grade IV: Life threatening * Grade V: Fatal

    Time frame: Up to 71 days post-dose

Secondary outcomes

  1. Maximum observed serum concentration (Cmax)

    Time frame: Up to 71 days post-dose

  2. Time to maximum observed serum concentration (tmax)

    Time frame: Up to 71 days post-dose

  3. Area under the serum concentration versus time curve from time zero to the last quantifiable concentration (AUCt)

    Time frame: Up to 71 days post-dose

  4. AUC from time zero to infinity (AUC∞)

    Time frame: Up to 71 days post-dose

  5. Terminal elimination rate constant (λz)

    Time frame: Up to 71 days post-dose

  6. Terminal half-life (t½)

    Time frame: Up to 71 days post-dose

  7. Total clearance (CL)

    Time frame: Up to 71 days post-dose

  8. Volume of distribution (Vd)

    Time frame: Up to 71 days post-dose

  9. Change from Baseline or Percent Change from Baseline in Levels of Complement Component C3b via Alternative Pathway (AP) of Complement Activity

    Time frame: Up to 71 days post-dose

  10. Change from Baseline or Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via the Alternative Pathway (AP) of Complement Activity

    Time frame: Up to 71 days post-dose

  11. Number of Participants with Antidrug Antibodies (ADAs) to NM8074

    Time frame: Up to 71 days post-dose

Other outcomes

  1. Change from Baseline or Percent Change from Baseline in Complement Component Factor B

    Time frame: Up to 71 days post-dose

  2. Change from Baseline or Percent Change from Baseline in Levels of Membrane Attack Complex via Classical Pathway (CP) of Complement Activity

    Time frame: Up to 71 days post-dose

  3. Change from Baseline or Percent Change from Baseline in Levels of Complement Component C3b via Classical Pathway (CP) of Complement Activity

    Time frame: Up to 71 days post-dose

07

Study locations

1 site
  • Covance Clinical Unit
    Dallas, Texas 75247, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2022, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Dec 8, 2022
StartActual
Aug 12, 2020
Primary completionActual
Jun 15, 2022
CompletionActual
Jun 15, 2022
Last update
Dec 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05642546
Lead sponsor
NovelMed Therapeutics
Collaborators
Labcorp Corporation of America Holdings, Inc
Responsible party
Sponsor
First posted
Dec 8, 2022
Start date
Aug 12, 2020
Primary completion
Jun 15, 2022
Completion
Jun 15, 2022
Last update
Dec 8, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxoprubart

Start the discussion